NYSE:TEVA Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis $40.32 -0.30 (-0.73%) As of 09:52 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Teva Pharmaceutical Industries Stock (NYSE:TEVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TEVA alerts:Sign Up Key Stats Today's Range$39.88▼$40.2650-Day Range$36.03▼$41.4452-Week Range$18.84▼$42.02Volume250,942 shsAverage Volume6.77 million shsMarket Capitalization$46.99 billionP/E Ratio67.16Dividend YieldN/APrice Target$45.92Consensus RatingModerate Buy Company Overview Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas. Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases. Key branded products have included Copaxone, Austedo, Ajovy and Uzedy, while the company also supplies generic and biosimilar medicines to hospitals, pharmacies and health care providers. Teva serves patients and health care systems in numerous markets across North America, Europe and other international regions. The company operates through research, manufacturing and commercial networks worldwide and is led by Richard Francis, who became president and chief executive officer in 2023.AI Generated. May Contain Errors. Read More Teva Pharmaceutical Industries Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreTEVA MarketRank™: 4.38524044225 of 5 starsTeva Pharmaceutical Industries scored higher than 88% of companies evaluated by MarketBeat, and ranked 64th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingTeva Pharmaceutical Industries has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on no strong buy ratings, 12 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTeva Pharmaceutical Industries has a consensus price target of $45.92, representing about 13.2% upside from its current price of $40.55.Amount of Analyst CoverageTeva Pharmaceutical Industries has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Teva Pharmaceutical Industries' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth52.00% Earnings GrowthEarnings for Teva Pharmaceutical Industries are expected to grow by 52.00% in the coming year, from $2.00 to $3.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Teva Pharmaceutical Industries is 67.58, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 36.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Teva Pharmaceutical Industries is 67.58, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 219.22.Price to Earnings Growth RatioTeva Pharmaceutical Industries has a PEG Ratio of 3.79. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioTeva Pharmaceutical Industries has a P/B Ratio of 5.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Teva Pharmaceutical Industries' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.58% of the float of Teva Pharmaceutical Industries has been sold short.Short Interest Ratio / Days to CoverTeva Pharmaceutical Industries has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Teva Pharmaceutical Industries has recently decreased by 5.18%, indicating that investor sentiment is improving significantly. Dividend0.8 / 5Dividend StrengthN/A Dividend YieldTeva Pharmaceutical Industries does not currently pay a dividend.Dividend GrowthTeva Pharmaceutical Industries does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Teva Pharmaceutical Industries will have a dividend payout ratio of 33.26% next year. This indicates that Teva Pharmaceutical Industries will be able to sustain or increase its dividend. News and Social Media3.4 / 5News Sentiment0.52 News SentimentTeva Pharmaceutical Industries has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Teva Pharmaceutical Industries this week, compared to 9 articles on an average week.Search Interest14 people have searched for TEVA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows12 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Teva Pharmaceutical Industries insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,644,285.00 in company stock.Percentage Held by Insiders0.54% of the stock of Teva Pharmaceutical Industries is held by insiders.Percentage Held by Institutions54.05% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Teva Pharmaceutical Industries' insider trading history. Receive TEVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TEVA Stock News HeadlinesUEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s DiseaseOctober 20 at 9:02 AM | finance.yahoo.comTeva Pharmaceutical Industries (NYSE:TEVA) Stock Price Expected to Rise, Barclays Analyst SaysOctober 17, 2026 | americanbankingnews.com80 Days Until the Pentagon Restricts Chinese Rare EarthsChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports to the U.S. With a January 1, 2027 deadline approaching, the Pentagon selected four companies to build critical mineral processing facilities on U.S. military bases. Only one was chosen for heavy rare earths - a Nasdaq-listed firm with an Ohio metallurgy facility under Pentagon contracts and rights to 80% of output from a major Canadian processing plant.October 22 at 1:00 AM | The Tomorrow Investor (Ad)MedinCell (ENXTPA:MEDCL) Stock Could Be Overvalued On FDA Approval NewsOctober 15, 2026 | finance.yahoo.comJ&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock DownOctober 15, 2026 | finance.yahoo.comNvidia (NVDA) vs. Bumble (BMBL): How the AI Gold Rush is Blinding Investors to Real-Value GemsOctober 15, 2026 | finance.yahoo.comIsrael Elections: AI Stocks, A Defense Winner And Oil Prices In FocusOctober 15, 2026 | finance.yahoo.comInsider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) Insider Sells $285,236.70 in StockSeptember 23, 2026 | insidertrades.comSee More Headlines TEVA Stock Analysis - Frequently Asked Questions How have TEVA shares performed this year? Teva Pharmaceutical Industries' stock was trading at $31.21 at the beginning of the year. Since then, TEVA shares have increased by 29.9% and is now trading at $40.55. How were Teva Pharmaceutical Industries' earnings last quarter? Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) issued its earnings results on Tuesday, June, 30th. The company reported $0.02 earnings per share for the quarter. The business earned $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a trailing twelve-month return on equity of 32.64%. Read the conference call transcript. Who are Teva Pharmaceutical Industries' major shareholders? Teva Pharmaceutical Industries' top institutional investors include Sumitomo Mitsui DS Asset Management Company Ltd (0.01%), Sowell Financial Services LLC (0.01%), Diversify Advisory Services LLC (0.01%) and Magnus Financial Group LLC. Insiders that own company stock include Richard D Francis, Eric A Hughes, Mark Sabag, Tal Zvi Zaks, Eliyahu Sharon Kalif, Christine Fox, Richard Daniell, Amir Weiss, Matthew Shields, Eric Drape, Brian Savage, Placid Jover, Roberto Mignone and Vikki L Conway. View institutional ownership trends. How do I buy shares of Teva Pharmaceutical Industries? Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Teva Pharmaceutical Industries own? Based on aggregate information from My MarketBeat watchlists, some other companies that Teva Pharmaceutical Industries investors own include NVIDIA (NVDA), GE Aerospace (GE), Intel (INTC), Tesla (TSLA), AT&T (T), Bank of America (BAC) and Micron Technology (MU). Company Calendar Last Earnings6/30/2026Today10/22/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TEVA's financial health is in the Green zone, according to TradeSmith. TEVA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:TEVA CIK818686 Webwww.tevapharm.com Phone(723) 914-8213Fax972-3923-4050Employees33,950Year Founded1901Price Target and Rating Average Price Target for Teva Pharmaceutical Industries$45.92 High Price Target$55.00 Low Price Target$40.00 Potential Upside/Downside+13.2%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)$0.60 Trailing P/E Ratio67.58 Forward P/E Ratio20.28 P/E Growth3.79Net Income$1.41 billion Net Margins4.08% Pretax Margin4.09% Return on Equity32.64% Return on Assets6.34% Debt Debt-to-Equity Ratio1.56 Current Ratio0.88 Quick Ratio0.67 Sales & Book Value Annual Sales$17.26 billion Price / Sales2.74 Cash Flow$3.70 per share Price / Cash Flow10.95 Book Value$6.88 per share Price / Book5.89Miscellaneous Outstanding Shares1,165,300,000Free Float1,159,003,000Market Cap$47.25 billion OptionableOptionable Beta0.89 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NYSE:TEVA) was last updated on 10/22/2026 by MarketBeat.com Staff. From Our PartnersMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | Sponsored80 Days Until the Pentagon Restricts Chinese Rare EarthsChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A ...Goldco Direct, LLC | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredSpaceX is worth trillions. This one's $14.It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork,...Behind the Markets | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
